Stelexis’ mission is to become the leading cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).


Stelexis proprietary platform is focused on identifying and isolating the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations, that drive the formation of primary and recurrent human tumors. Stelexis will utilize this powerful platform as a target identification engine and drug discovery and development tool to address unmet needs in multiple cancer indications.



As in many other cancers, relapse continues to be the leading cause of death in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), where overall cure rates remain below 20%.

The treatment paradigm and clinical outcome in AML has not significantly improved in the past four decades, particularly for the majority of patients over 55 years of age. Stelexis aims to change this by targeting disease-initiating, pre-leukemic stem cells and their malignant progression. This offers a fundamentally novel approach for potentially curative strategies in leukemias and other cancer types.

Stelexis initial use of the platform utilizing and analyzing human AML and MDS samples, lead to the identification of a number of novel molecular targets, believed to be key players in the cancerous process. This effort has produced several drug discovery programs, currently at the preclinical stage.

The overarching strategy of Stelexis is to develop drugs that target and eliminate disease-initiation pre-leukemic and, ultimately, pre-cancerous stem cells.